Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Hansa Biopharma AB's Revenue for the
three
months ended in Mar. 2026 was kr34.6 Mil. Hansa Biopharma AB's Total Assets for the quarter that ended in Mar. 2026 was kr1,164.5 Mil. Therefore, Hansa Biopharma AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.03.
Asset Turnover is linked to ROE % through Du Pont Formula. Hansa Biopharma AB's annualizedROE % for the quarter that ended in Mar. 2026 was 882.41%. It is also linked to ROA % through Du Pont Formula. Hansa Biopharma AB's annualizedROA % for the quarter that ended in Mar. 2026 was -67.44%.
Hansa Biopharma AB (OSTO:HNSA) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
Hansa Biopharma AB's annulizedROE % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Hansa Biopharma AB's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Hansa Biopharma AB Asset Turnover Related Terms
Hansa Biopharma AB Asset Turnover Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:HNSA vs VRTX, REGN, ALNY: Asset Turnover Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Hansa Biopharma AB (OSTO:HNSA) has a Asset Turnover of 0.03 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Asset Turnover too high?
Hansa Biopharma AB's current Asset Turnover is 0.03. Overall, Hansa Biopharma AB has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Asset Turnover compare to VRTX and REGN?
Hansa Biopharma AB's Asset Turnover of 0.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Asset Turnover is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.52, compared to a current price of kr35.10 — trading 43.1% above its estimated fair value. The current Asset Turnover is 0.03. Hansa Biopharma AB's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current Asset Turnover is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr35.10 is trading 43.1% above its estimated GF Value™ of kr24.52.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
Asset Turnover: 0.03
GF Value™: kr24.52 vs. price of kr35.10 (43.1% above fair value)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for OSTO:HNSA
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
